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Abstract
A subgroup of HER2-overexpressing breast tumours co-expresses p95HER2, a truncated HER2 receptor that retains
a functional HER2 kinase domain but lacks the extracellular domain, thus impairing trastuzumab binding. We
evaluated p95HER2 expression in 99 frozen breast carcinoma samples by western blot analysis. The HER2-positive
cell line BT474 treated with pervanadate or pronase was used as a positive control for p95HER2 expression.
Immunohistochemistry was performed on parallel formalin-fixed, paraffin-embedded sections of the same case
series using antibodies directed against either the intra- or extra-cellular binding domain of HER2. In particular,
biotinylated trastuzumab (BiotHER) was used to evaluate the binding capacity of the humanized antibody. To avoid
a subjective evaluation of the score values and the percentage of immunostained cells, the slides were scanned and
automatically analysed. The number of cases with HER2 overexpression (score 3+) and HER2 gene amplification
was higher in the p185HER2-positive/p95HER2-positive samples than in the p185HER2-positive/p95HER2-negative
group. Automated analysis confirmed a significantly higher percentage of 3+ scored cells in p95HER2-positive
cases. Conversely, the percentage of 2+ scored cells was higher in p95HER2-negative cases. The status of the
HER2 extracellular domain was then studied using flow cytometry on BT474 cells after pronase enzymatic
digestion using trastuzumab and pertuzumab, while the presence of HER2-HER3 dimers was studied using a
proximity-ligation assay. In vitro experiments showed that short-term pronase digestion of BT474 cells produced
two HER2 fragments (of 95 and 150 kDa, detectable in tissue specimens as well), increased the binding
affinity of trastuzumab, reduced the rate of HER2–HER3 dimers, and did not interfere with pertuzumab-binding
capacity. In conclusion, the presence of p95HER2 as detected by western blot analysis does not compromise the
immunohistochemical detection of HER2. Our data suggest that a reduction of the receptor steric hindrance as
induced by enzymatic shedding may facilitate the binding capacity of trastuzumab.
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Introduction
The human proto-oncogene HER2 encodes for the full-
length membrane-spanning receptor p185HER2. Over-
expression of p185HER2 plays a pathogenic role in
approximately 20% of breast cancers [1]. The large
110 kDa extracellular domain (ECD) of HER2 consists
of 621 amino acids and is subdivided into four domains
(I–IV) [2,3]. The HER2 ECD constitutively adopts
an active extended conformation, which is acquired
by other Epidermal Growth Factor Receptors (EGFRs)
only after ligand binding. This structural feature of
ECD favours the homo- and hetero-dimerization of
HER2, thus encouraging activation of the intracel-
lular tyrosine kinase domain and triggering down-
stream signalling events [4]. Pertuzumab, a humanized
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monoclonal antibody, binds to HER2 near the centre of
domain II and inhibits HER2 dimerization with other
members of the EGFR family [5,6]. In contrast, bind-
ing of trastuzumab to domain IV of HER2 does not
interfere with heregulin-induced HER2–HER3 dimer
formation but prevents HER2 shedding and inhibits
intracellular signalling [7].
Approximately 30% of HER2-positive patients
express a variety of receptor fragments sized between
90 and 115 kDa. These are collectively known as
p95HER2 carboxy-terminal fragments (CTFs) [8]. In
breast cancer, HER2-CTFs may be synthesized [9,10]
or produced by an enzymatic sheddase [11]. A slow
proteolytic cleavage performed by metalloproteases
can occur at a site proximal to the transmembrane
domain [12–14], thus generating a fragment of 95 kDa
that retains kinase activity [15–19]. It is yet to be
determined whether p95HER2 levels in breast tumours
are directly linked to the HER2 concentration in the
serum [20–22]. The rapid and potent shedding of the
HER2 ECD produced in vitro by pervanadate [23],
a general inhibitor of protein-tyrosine phosphatases
with a non-specific metalloprotease activation capac-
ity, induces an increase in p95HER2 levels in BT474
breast cancer cells and delivers the trastuzumab epi-
tope to the cell culture medium [16]. Scaltriti et al
[14] hypothesized that the tumours expressing p95HER2
in the absence of the trastuzumab-binding extracellular
domain may be resistant to the humanized antibody.
However, a translational investigation from the neoad-
juvant GeparQuattro study (incorporating chemother-
apy plus trastuzumab treatment) showed that p95HER2
expression, measured using a monoclonal antibody that
specifically recognizes the 611 CTFs by immunohisto-
chemistry (IHC), indicates a response to trastuzumab
[24].
In previous studies using biotinylated trastuzumab
(BiotHER) as the primary antibody for IHC [25,26],
we demonstrated that the trastuzumab binding site
was only detectable in approximately 50% of HER2-
amplified breast cancers, while the reported percent-
age of HER2 overexpression using anti-intracellular
domain (ICD) antibodies in amplified breast cancers
is approximately 90% [27]. Similarly, we previously
showed a lower percentage of ECD overexpression
using the TAB250 antibody compared with the ICD
expression as evaluated by CB11 in amplified breast
cancers [28].
Taking these data together, our hypothesis was that
the expression of HER2-truncated forms could reduce
the availability of the epitopes necessary for a reaction
with specific anti-ECD antibodies. Therefore, we eval-
uated the expression of the HER2-truncated forms by
western blot (WB) analysis in a series of breast carcino-
mas and compared the level of expression with the IHC
results using antibodies directed against both the ICD
and the ECD of HER2. The results were compared and
validated with those obtained in vitro in BT474 HER2-
positive breast cancer cells after enzymatic induction
of HER2 truncation.
Materials and methods
Tissue samples
Paired formalin-fixed, paraffin-embedded (FFPE) tis-
sue blocks and snap-frozen specimens (stored at
−80 ◦C in frozen tissue matrix OCT) from 99 breast
cancers were obtained from the pathology files of the
authors’ institutions. The fixation was performed in
buffered formalin at room temperature for 24–48 h.
Permission for the project was obtained from the Insti-
tutional Review Board, and the study was conducted
in compliance with the ethical regulatory requirements
for the handling of biological specimens from tumour
banks of the participating institutions (ie samples were
exclusively available for research purposes in retro-
spective studies). The same Institutional Ethics Review
Board agreed that written consent from the patients was
not required, given that the study did not interfere with
diagnosis or treatment decisions. The patient data were
anonymized prior to analysis.
Fluorescence in situ hybridization (FISH)
FISH was performed using probes for HER2 (17q12)
and CEP17 (Vysis, Inc, Downers Grove, IL, USA)
as previously reported [29]. The analysis was per-
formed by selection and automated acquisition of
six invasive areas on each slide using the Metafer
Scanning System (Carl Zeiss MetaSystems GmbH,
Baden-Wuttenberg, Germany) and AxioImager epiflu-
orescence microscope. PathVysion V2 software (FDA
approved) was used to analyse the results. The cases
were scored according to the ASCO guidelines [30].
Immunostaining
The expression of the ICD was evaluated using the
Herceptest kit (DAKO, Glostrup, Denmark) on a
Dako Autostainer and CB11 (diluted 1 : 200; Novocas-
tra Laboratories, Newcastle-upon-Tyne, UK) using a
Bond automated stainer (Menarini Diagnostics, Flo-
rence, Italy). To evaluate the effect of p95HER2 expres-
sion on ECD detection via IHC, the sections were
processed using the TAB250 mouse monoclonal anti-
body (Zymed, San Francisco, CA, USA). In addition,
to evaluate the trastuzumab-specific binding site, we
used BiotHER as previously reported [25,26]. Briefly,
1 mg of trastuzumab was diluted in saline solution
and dialysed overnight in 0.1 M Na2CO3, pH 8.5. To
a 1 ml solution, 0.12 ml of aminohexanoyl-biotin-N-
hydroxysuccinimide ester (AH-BNHS; Biospa, Milan,
Italy) was added, gently mixed for 4 h at room tem-
perature, and dialysed in phosphate buffered saline. We
tested the ECD overexpression with or without pre-
treatment with pronase, diluted to 0.1%. Endogenous
peroxidases were inhibited by incubating sections with
6% H2O2 for 7 min. The sections were then incubated
with the primary antibodies diluted in PBS with 1%
BSA (TAB250, 1 : 20; BiotHER, 1 : 100) for 30 min
at room temperature. After rinsing in PBS, EnVision+
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System Labelled Polymer-HRP (Dako) anti-mouse and
HRP-conjugated streptavidin (diluted 1 : 50; BioGenex,
San Ramon, CA, USA) were used to reveal TAB250
and BiotHER staining, respectively. The reaction was
developed using a solution of 3,3′-diaminobenzidine
and H2O2 for 5 min. The nuclei were counterstained
with Mayer’s haemalum.
To avoid a subjective evaluation of the percentage
of immunostained cells in cancer tissues and to assess
the intra-tumour heterogeneity of HER2 expression,
BiotHER and CB11-stained slides were scanned and
analysed using a ScanScope XT automated scanning
system (Aperio Technologies, Vista, CA, USA) and the
integrated FDA-approved software. Each section was
subdivided into six quadrants in which eight to ten
tumour foci were randomly selected (Figure 1). The
score results (percentage of cells scored as 3+, 2+,
and 1+) of each quadrant were recorded. A variance
analysis comparing the percentage of positive cells in
each quadrant was performed. The mean percentage of
the different score values in each quadrant was then
compared with the p95HER2 status as defined by WB.
Statistical analyses were performed using Student’s
t-test assuming unequal variances (software freely
available at http://studentsttest.com/). The sections
obtained from BT474 blocks (control and test) were
processed with the same IHC protocols reported above.
In vitro induction of p95HER2
To induce p95HER2 production in BT474, cells were
treated with freshly prepared pervanadate (0.5 M
sodium orthovanadate and 0.5 M H2O2) [16]. After
overnight starvation (DMEM with 0.5% FCS), the cells
were treated with 0.1 or 1 mM pervanadate for 30, 60,
90, and 180 min. At each time point, the level of sol-
uble p97–115HER2 (the soluble circulating fragment of
p185HER2) was analysed in the supernatant using the
human sHER2 enzyme-linked immunosorbent assay
(ELISA) kit according to the manufacturer’s instruc-
tions (BMS207; Bender MedSystems GmbH, Vienna,
Austria). The results were normalized against non-
conditioned medium. To test the effect on cell viability
of H2O2 added to orthovanadate to obtain pervanadate,
BT474 cells were incubated for 90 min either with
1 mM H2O2 alone or with the addition of 500 U/ml
of catalase [31] after mixing orthovanadate and H2O2.
Alternatively, at confluence, BT474 cells were
washed with PBS and treated with pronase (0.1%
and 0.02% in PBS) at room temperature for 10 min.
The cells were then collected and washed twice with
PBS supplemented with 3× protease inhibitors cock-
tail (complete, EDTA-free; Roche Diagnostics SpA,
Monza, Milan, Italy).
Cell growth was monitored in flasks with an EVOS
inverted microscope (Advanced Microscopy Group,
Bothell, WA, USA), and cell viability was assessed
using trypan blue vital staining. Each experiment was
performed in triplicate. The paraffin-embedded blocks
were prepared from cell pellets obtained after fixation
in buffered formalin.
Western blot (WB) analysis
After each treatment described above, the expression of
HER2 was assessed by WB on BT474 cells. From the
breast cancer specimens, ten frozen sections containing
approximately 1 cm2 of viable tumour cells were
analysed. The adequacy was verified on haematoxylin
and eosin-stained sections before and after cutting. One
Layer Attributes
Her2 Score
(3+) Percent Cells
(2+) Percent Cells
(1+) Percent Cells
(0+) Percent Cells
3.
50.29
14.02
35.28
0.4056
A B
C
Figure 1. Automated IHC analysis. Micrographs illustrating an example of quadrant selection (A), the APERIO software result layout (B),
and a table of the percentage of positivity (C).
Copyright  2012 Pathological Society of Great Britain and Ireland. J Pathol 2013; 229: 390–399
Published by John Wiley & Sons, Ltd. www.pathsoc.org.uk www.thejournalofpathology.com
HER2 truncation and trastuzumab binding in breast cancer 393
out of 99 cases showing only in situ carcinoma on
the frozen section was discarded. The frozen sections
were collected in tubes and washed with cold PBS
to remove the OCT and blood residues. The samples
were lysed at 4 ◦C for 30 min in RIPA lysis buffer
(50 mM Tris–HCl, pH 7.5; 150 mM NaCl; 1% Triton
X-100; and 0.1% SDS) with protease inhibitors. The
total protein extracts were quantified with the BCA
protein assay (Thermo Fisher Scientific Inc, Rockford,
IL, USA), divided into aliquots of 25 µg, and stored at
−80 ◦C.
After the addition of 5× loading buffer, each sample
was boiled for 5 min and loaded onto an 8% polyacry-
lamide gel. Each gel contained a control lane loaded
with 25 µg of protein extracted from pervanadate-
treated BT474 cells as a marker for p95HER2.
Electrophoresis was performed in TGS buffer; after
separation, proteins were transferred to a nitrocellulose
membrane. After saturation with TBS and 5% milk,
the membrane was immunoblotted either with anti-
HER2 (A0485, polyclonal antibody; Dako, Glostrup,
Denmark) at 1 : 1000 or with anti-actin at 1 : 800 as a
loading control. Both antibodies were diluted in TBS
with 5% BSA and incubated overnight at 4 ◦C. The
membrane was washed and incubated with an anti-
rabbit peroxidase-labelled secondary antibody. Finally,
the membrane was developed with ECL luminol (Bio-
Rad, Hercules, CA, USA).
p185HER2 was considered overexpressed (++) if the
WB band was greater than or equal to the p185HER2
level in 25 µg of BT474 cells. Lower p185HER2 expres-
sion levels were classified as p185HER2 (+). Specimens
were scored as positive for p95HER2 (+) if a distinct
band was present at the same molecular weight as
the p95HER2 pervanadate-induced band in BT474 cell
extracts.
Flow cytometry
To obtain a single cell suspension, BT474 cells were
detached with trypsin/EDTA and collected into a 50 ml
tube with 20 ml of DMEM medium at 37 ◦C for 1 h
to allow the replacement of all the surface molecules
eventually digested by trypsin. Afterwards, four tubes
of 106 cells each were centrifuged. Two cell pellets
were incubated for 10 min at room temperature with
100 µl of 0.1% pronase; controls were kept in PBS.
To ensure complete pronase inactivation, the cells were
washed once with DMEM and twice with PBS supple-
mented with 2× protease inhibitors. The cells were
then incubated at room temperature for 30 min with
trastuzumab or pertuzumab (Genentech, Inc, South San
Francisco, CA, USA), both at a final concentration of
100 ng/ml, followed by a FITC-conjugated anti-human
secondary antibody. The stained cells were analysed
with a Canto II flow cytometer (Becton Dickinson, San
Jose, CA, USA).
Figure 2. Western blot analysis performed on breast can-
cer tissues. p185HER2++/p95HER2−cases (lanes 1, 2, 4,
and 6), p185HER2++/p95HER2+ cases (lanes 3 and 7),
p185HER2+/p95HER2−cases (lanes 5, and 8), and pervanadate-
treated BT474 cells (lane 9). A subgroup of cases with high
expression of p185HER2 and p95HER2 showed a 150 kDa fragment
(lanes 3 and 7).
Immunoprecipitation analyses
The pronase-treated BT474 cells were lysed in RIPA
buffer as described above. Total extract aliquots of
500 µg were incubated with 2 µg of trastuzumab
or pertuzumab at 4 ◦C overnight under gentle agita-
tion. Twenty microlitres of sepharose-protein A and
sepharose-protein G beads was added. After incuba-
tion for 2 h at 4 ◦C, the sepharose beads were washed
and rinsed with 1× loading buffer. The immunopre-
cipitated proteins and 25 µg of control total extracts
were analysed by western blot using the same protocol
described above.
Proximity ligation assay (PLA)
All reagents used for the PLA analysis were from Olink
Bioscience (Uppsala Science Park, Uppsala, Sweden).
The PLA reactions were performed following the man-
ufacturer’s instructions using anti-HER2 (A0485 poly-
clonal diluted 1 : 300) and anti-HER3 (monoclonal anti-
body clone 6F12 diluted 1 : 100; Lab Vision, Thermo
Fisher Scientific Inc, Kalamazoo, MI, USA) as primary
antibodies. Student’s t-test was used assuming unequal
variances.
Results
Correlation of p95HER2 and IHC results in breast
cancer specimens
By WB analysis, p185HER2 was detectable in 50 cases.
Forty samples showed HER2 amplification by FISH.
Among these amplified cases, 20 were p185HER2++,
and 12 of these also expressed p95HER2 by WB
(Figure 2). In the latter subgroup of cases, five showed
a 150 kDa fragment as well. Twenty cases p185HER2+
were negative for p95HER2. Two out of seven cases
with HER2 gene gain (less than six gene signals per
cell) had high expression levels of p185HER2, but not
p95HER2. Three cases with very low expression levels
of p185HER2 did not show any genetic alterations.
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Table 1. Correlation of p185HER2 and p95HER2 expression by western blot and score 3+ immunohistochemical results (>10% of
HER2-positive cells with strong and complete membrane expression) with anti-HER2 antibodies in 50 breast cancers
Immunohistochemistry score 3+ of HER2
Anti-intracellular domain Anti-extracellular domain
Western blot CB11 (%) A048 (%) TAB250 (%) BiotHER (%)
p185++/p95+ 9/12 (75) 7/12 (58) 8/12 (67) 7/12 (58)
p185++/p95− 3/10 (30) 4/10 (40) 4/10 (40) 4/10 (40)
Figure 3. Pronase antigen retrieval. A breast carcinoma sample immunostained with BiotHER following routine IHC procedure (no antigen
retrieval) (A). Pronase antigen retrieval increases both the percentage and the intensity of immunostaining (B).
The effect of p95HER2 expression on the HER2
IHC expression of breast cancer tissues is shown in
Table 1. The number of cases showing HER2 over-
expression (score 3+; >10% of HER2+ cells with
strong and complete membrane staining) was higher
in the series scored as p185HER2++/p95HER2+ by WB
than in the series p185HER2++/p95HER2−. This result
was confirmed using both the anti-ICD (Herceptest
and CB11) and the anti-ECD (TAB250 and BiotHER)
antibodies following antigen retrieval with pronase.
Pronase increased the 3+ scored cells with Bio-
tHER and TAB250 (Figure 3) antibodies compared
with sections not enzyme treated, regardless of the level
of p95HER2.
Automated analysis of CB11 and BiotHER im-
munostaining of breast cancer confirmed a significantly
higher percentage of 3+ scored cells in p95HER2+
cases compared with the p95HER2−
(p < 0.005; Figures 4A and 4D). In contrast, the per-
centage of 2+ scored cells was higher in p95HER2−
cases (p < 0.005; Figures 4B and 4E). In both series,
the immunostaining was homogeneously distributed.
The percentage of cells scored 1+ was similar in the
two groups (p > 0.005; Figures 4C and 4F). No sig-
nificant differences among the 3+ (p >> 0.005), 2+
(p >> 0.005), and 1+ (p >> 0.005) quadrants were
observed at variance analysis, indicating uniform quad-
rant selection.
p95HER2 induction and cell viability in BT474
Incubation of BT474 cells with pervanadate (1 mM)
induced a shedding of HER2 ECD that increased in a
time-dependent manner, as shown by the ELISA test
(Figure 5A); this occurred in parallel to the p95HER2
increase (Figure 5B). However, BT474 cells rapidly
detached from the culture plate, and cell viability
was highly compromised by the treatment with per-
vanadate even after 30 min of exposure (Figures 6A
and 6B), with almost 80% cell death. The toxic
effect of pervanadate was confirmed when catalase
was used to block excess H2O2 (Figure 6C). In con-
trast, H2O2 alone did not induce any sign of cellular
stress (Figure 6D). Lower concentrations of pervana-
date (0.1 mM) did not induce p95HER2 even after 3 h
of treatment (Figure 5C) but maintained the cytotoxic
effect.
Pronase treatment digested p185HER2 and generated
two fragments (Figure 7), and did not compromise cell
viability, as shown by EVOS examination (Figures 6E
and 6F) and trypan blue assay. The cells treated with
0.02% pronase showed a thin p95HER2 band, a clear
and intense band at 150 kDa, and maintained strong
expression of p185HER2. Higher pronase concentrations
(0.1%) led to a further increase in the 95 kDa and
150 kDa band signals coupled with an almost complete
disappearance of the p185 band (Figure 7).
Trastuzumab and pertuzumab binding
Membrane immunostaining with BiotHER following
pronase treatment increased in intensity (Figure 8).
Flow cytometry on control BT474 cells showed 67%
of cells with higher trastuzumab affinity and the
remaining 33% with lower affinity for trastuzumab
(Figure 9A). After 10 min of pronase exposition, 94%
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Figure 4. Automated analysis of HER2 extracellular domain expression by IHC. Distribution of the mean percentage of BiotHER expression
within six different fields (ie section quadrants Mq1–6) (A–C). Differences between p95HER2-positive (red) and -negative (green) cases are
statistically significant in 3+ score (A, D) and 2+ score (B, E) categories, whereas no statistically significant difference is observed in 1+
scored cases (C, F).
of cells showed high trastuzumab binding (Figure 9B).
By immunoprecipitation, we showed that the 150 kDa
HER2 fragment induced by pronase treatement still
bound trastuzumab (Figure 10). Pronase treatment did
not affect the binding capacity of pertuzumab, as shown
by flow cytometry (Figures 9C and 9D) and confirmed
by immunoprecipitation assay (Figure 10).
HER2–HER3 dimer dissociation
The PLA performed using anti-HER2 and -HER3
antibodies allowed for the analysis of heterodimers
in BT474. The mean number of signals per cell
(mean = 20.30; mode = 18; standard deviation =
10.53; n = 315) in the control was significantly higher
(p < 0.005), as determined by a t-test analysis, than
the mean number of signals per cell (mean = 13.76;
mode = 5; standard deviation = 9.88; n = 384) in the
BT474 pronase-treated cells (Figure 11).
Discussion
Our first objective was to evaluate whether p95HER2
may impair the trastuzumab-binding epitope. Using
WB and IHC analyses, we confirmed the results by
Molina et al [18] demonstrating that p95HER2 frag-
ments in breast cancer tissues are generally associated
with high levels of p185HER2. However, in contrast to
our expectations, we observed that the IHC expression
of the trastuzumab epitope as detected by BiotHER in
breast cancer tissue was higher in p95HER2+ cases than
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Figure 5. Induction of HER2 shedding on BT474 cells by
pervanadate. HER2 ECD levels in culture medium as evaluated
by ELISA increase after 1 mM pervanadate treatment (A), which in
parallel induce p95HER2 as shown by western blot (B). No p95HER2
induction was observed using 0.1 mM pervanadate (C).
in cases with similar high levels of p185HER2 but nega-
tive for p95HER2. This result could explain the response
of tumours that expressed p95HER2 to trastuzumab ther-
apy measured by IHC as shown in the neoadjuvant
GeparQuattro study [24].
A possible explanation for this unexpected increase
in immunoreactivity of the anti-HER2 antibodies in the
presence of truncated HER2 may be the reduction of
the antigen ‘steric hindrance’. It has been demonstrated
that the number of antigen molecules that are bound to
the cell surface could significantly affect the ability
of antibodies to bind, causing steric hindrance [32].
If the antigenic determinants are closely spaced on
the cell surface, spatial interference may result such
that a smaller distance between the antigenic determi-
nants leads to a greater likelihood of reduced antibody
binding. In previous experiments, Valabrega et al [33]
were able to modulate the expression of HER2 in
SKBR3 HER2-overexpressing breast cancer cells by
using small interfering RNAs at different concentra-
tions. In agreement with our hypothesis, it was shown
that a HER2 reduction up to 70%, as measured by
WB analysis and flow cytometry, still corresponded to
an immunoreactivity of cells scored as 3+ and that
Figure 6. Effects of proteolytic treatments on cell cultures. Control
BT474 cells (A, E). Following 1 mM pervanadate alone (B) or
pervanadate and catalase treatment (C), BT474 cells detach from
the dish and die (B). Cell viability is not compromised in BT474
cells treated with 1 mM hydrogen peroxide alone (D) and in BT474
cells treated with 0.1% pronase (F).
Figure 7. Pronase induced HER2 cleavage. Treatment with 0.1%
pronase (lane 1) and 0.02% pronase (lane 2) in BT474 cells leads
to p185HER2 cleavage and the formation of 150 kDa and 95 kDa
bands. Control BT474 cells (lane 3).
HER2 reduction up to 40% rendered cancer cells more
sensitive to trastuzumab treatment.
To study the effect of HER2 truncation in vitro,
as suggested by others [16], we used pervanadate,
a protein-tyrosine phosphatase inhibitor that induces
HER2 shedding in BT474 cells through non-specific
metalloprotease activity. Unfortunately, we found per-
vanadate to be highly toxic. An alternative method
to test our hypothesis was to simulate proteolysis
by treating cells directly with a cocktail of proteases
known as pronase, a mixture of at least ten proteases
[34] commonly used in IHC for antigen retrieval of
FFPE tissues. Digestion using pronase-based solutions
is designed to break the protein cross-links and unmask
the antigens and epitopes in FFPE tissue sections,
enhancing the antibody staining intensity [35]. In
addition, pronase treatment of high-molecular-weight
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Figure 8. Effects of proteolytic treatments on the expression of
trastuzumab binding site in BT474 cells. BiotHER staining in control
BT474 cells (A), in vitro pronase-treated cells (B), or pronase antigen
retrieval of sections cut from FFPE cell blocks (C). Stronger andmore
diffuse staining is observed in BT474 cells treated with pronase
(B) and in sections following pronase antigen retrieval (C).
glycoproteins is a useful method for obtaining glyco-
protein fragmentation without significant loss of bio-
logical activity [36]. We demonstrated that pronase
treatment of BT474 cells led to a proteolytic cleav-
age of HER2 with the formation of 95 kDa and
150 kDa fragments without affecting cell viability.
In turn, this proteolysis increased trastuzumab affin-
ity, did not affect pertuzumab-binding capacity, and
reduced HER2–HER3 dimer formation in breast can-
cer cells. The principal explanation for the triple effect
of pronase could be the unmasking of the trastuzumab
antigenic epitope and the shedding of domain I that
leads to the formation of the 150 kDa fragment. This
HER2 fragment is likely to maintain the integrity of the
pertuzumab-binding domains, while the blocking of the
interaction of domain I with domain III may inhibit the
open conformation of HER2 and prevent dimer forma-
tion [5,37–39]. By WB, we showed that the 150 kDa
fragment is present in human breast cancer tissues as
well.
The size of the antibody molecule (150 kDa for IgG)
may be another source of interference, particularly if
the epitopes are closely spaced. Thus, steric hindrance
is likely to be intensified when the antibodies have been
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Figure 9. Flow cytometry analysis on BT474 cells. Flow cytometry
analysis on control BT474 cells shows two populations, one (67% of
cells) with high trastuzumab affinity compared with the remaining
33% with lower affinity (A). After 10 min of pronase exposition,
there is a shift to 94% of cells with high affinity (B). The binding
capacity of pertuzumab is not affected by pronase treatment (C,
D).
Figure 10. Pertuzumab and trastuzumab binding site. Immuno-
precipitated HER2 protein using pertuzumab or trastuzumab shows
a band at 180 kDa in control (lanes 1 and 3) and at 150 kDa
in pronase-treated (lanes 2 and 4) BT474 cells, confirming the
presence of the antibody binding site.
labelled with other molecules such as biotin. In our
IHC tissue protocol, the effect of trastuzumab biotiny-
lation on the avidin–biotin reaction was controlled by
using aminocaproate, which limits the steric hindrance
by providing a six-carbon spacer to biotin and thus
improves accessibility to the binding site on avidin.
In conclusion, we have shown that the presence
of p95HER2 increases the trastuzumab-binding capacity
in cancer tissues. The shedding phenomenon induced
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Figure 11. PLA analysis on HER2/HER3 dimer. Dimers are identified by the fluorescent signals (red spots): a higher number of dimers is
observed in control BT474 cells (A) than in pronase-treated BT474 cells (B).
in vivo by metalloprotease and in vitro by pronase
could thus improve the binding of antibodies with
specific HER2 epitopes and allow trastuzumab to more
efficiently reach its epitope by reducing the steric
hindrance of cancer cells that may carry millions of
p185HER2 molecules on their surface.
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